HOME / Notice / News / EN
Acquired US patent for NK cell culture technology of NKCL Bio Group NKCL Bio Group (Chairman Shin Dong-hwa) announced that it had obtained a U.S. patent for NK cell culture technology. Recently, NKCL Bio Group successfully completed pre-clinical trials on the company's NK cell therapy pipeline for li...
[China-ROK (Changchun) International Cooperation Demonstration Zone Project, spurs the construction of a medical complex] A delegation from the 'China-ROK (Changchun) International Cooperation Demonstration Zone' (hereafter referred to as Changchun Demonstration Zone), an international industrial coo...
NKCL Bio Group, a high-tech biopharmaceutical manufacturing company, has obtained a cell processing facility permit under the Advanced Regenerative Bio Act from the Ministry of Food and Drug Safety(MFDS). Accordingly, NKCL Bio Group announced on the 24th that it will focus on the cell therapy busines...
NKCL Bio Group (Chairman Donghwa Shin), an advanced biopharmaceutical manufacturing company, announced on the 22nd that it had obtained permission for a cell processing facility based on the advanced regenerative bio method from the KFDA. NKCL Bio Group acquired permission to 'Manufacturing of Advanc...
As part of the policy pledge of the new government in 2022, in relation to fostering the advanced bioindustry, which is attracting attention as a growth engine industry, pharmaceutical and bio companies are announcing the latest biopharmaceutical manufacturing permits. This is interpreted as ‘legal ...